DOK6 promoter methylation serves as a potential biomarker affecting prognosis in de novo acute myeloid leukemia.

ABSTRACT:

Background

Downstream of tyrosine kinase 6 (DOK6), which is specifically expressed in the nervous system, was previously recognized as an adapter only in neurite outgrowth. Recent studies also demonstrated the potential role of DOK6 in solid tumors such as gastric cancer and breast cancer. However, previous studies of DOK6 have not dealt with its roles in myeloid malignancies. Herein, we verified the promoter methylation status of DOK6 and further explored its clinical implication in de novo acute myeloid leukemia (AML).

Methods

A total of 100 newly diagnosed adult AML patients were involved in the current study. DOK6 expression and methylation were detected by real-time qPCR and methylation-specific PCR (MSP), respectively. Bisulfite sequencing PCR (BSP) was performed to as

SUBMITTER: Sun GK 

PROVIDER: S-EPMC6797566 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature